085810.KQ
Alticast Corporation
KOSDAQKRWEQUITY
DELAYED
Last price
1,665.00
▼ 69.00 (3.98%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
1,670.00
Prev close
1,734.00
Day high
1,750.00
Day low
1,626.00
Volume
5.80K
Market cap
$21.57B
P/E (TTM)
—
52W range
1,050.00 – 3,620.00
Day trading desk
Gap from prior close
-3.69%
Prior close 1,734.00
VWAP
1,678.49
-0.80% from price
Relative volume
0.25×
Quiet session
Session range
7.63%
1,626.00 – 1,750.00
Position in range
31%
Mid range
ATR (14D)
95.71
5.75% of price
Prior day high
1,735.00
PDH
Prior day low
1,650.00
PDL
Bid / ask spread
—
Quote not published
Session volume
7.01K
Avg 28.09K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-8.62%
-7.4%
1M
-4.26%
-7.6%
3M
-10.44%
-12.8%
6M
-42.88%
-54.8%
YTD
-43.27%
-55.2%
1Y
-44.87%
-65.0%
3Y
-80.72%
-155.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on 085810.KQ open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap$21.57B
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $53.17B | $5.68B | $5.66B | $7.24B | +835.9% |
| Operating revenue | $53.17B | $5.68B | $5.66B | $7.24B | +835.9% |
| Cost of revenue | $39.86B | $3.26B | $3.90M | $158.96M | +1,122.4% |
| Gross profit | $13.31B | $2.42B | $5.65B | $7.09B | +449.9% |
| Research & development | $6.38M | $21.27M | $15.14M | $69.98M | -70.0% |
| Selling, general & admin | $2.06B | $2.28B | $2.16B | $3.64B | -9.8% |
| Total operating expense | $9.78B | $5.92B | $9.39B | $15.97B | +65.1% |
| Operating income | $3.53B | -$3.50B | -$3.73B | -$8.89B | +200.9% |
| Net interest income | $325.96M | -$918.48M | -$349.67M | -$424.35M | +135.5% |
| Pre-tax income | $855.58M | -$15.83B | -$20.04B | -$16.39B | +105.4% |
| Tax provision | $842.78M | $59.21M | $84.09M | $5.85M | +1,323.3% |
| Net income | -$813.30M | -$13.03B | -$25.97B | -$17.82B | +93.8% |
| Net income to common | -$813.30M | -$13.03B | -$25.97B | -$17.82B | +93.8% |
| Basic EPS | -80.00 | -2,195.00 | -4,495.00 | -3,080.00 | +96.4% |
| Diluted EPS | -80.00 | -2,195.00 | -4,495.00 | -3,080.00 | +96.4% |
| EBIT | $1.27B | -$14.23B | -$18.64B | -$15.28B | +108.9% |
| EBITDA | $2.49B | -$13.38B | -$17.77B | -$14.05B | +118.6% |
| Basic shares | 10.17M | 5.94M | 5.78M | 5.78M | +71.2% |
| Diluted shares | 10.17M | 5.94M | 5.78M | 5.78M | +71.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $7.00B | $23.32B | $1.31B | $989.11M | — | -70.0% |
| Cash & short-term investments | $21.12B | $23.32B | $1.31B | $1.08B | — | -9.4% |
| Accounts receivable | $6.88B | $1.63B | $1.60B | $1.88B | — | +322.5% |
| Inventory | — | — | — | $159.88M | $163.87M | — |
| Total current assets | $38.89B | $28.08B | $10.33B | $9.87B | — | +38.5% |
| Property, plant & equipment | $2.83B | $414.79M | $3.09B | $4.46B | — | +582.4% |
| Goodwill & intangibles | $6.11B | $9.16M | $3.74B | $7.33B | — | +66,635.3% |
| Total assets | $74.86B | $44.79B | $50.19B | $69.96B | — | +67.1% |
| Total current liabilities | $18.28B | $7.11B | $21.24B | $12.68B | — | +157.1% |
| Current debt | $4.60B | $1.43B | $4.13B | $290.60M | — | +223.0% |
| Long-term debt | $1.25B | — | $44.40M | $111.00M | $200.00M | — |
| Total debt | $6.59B | $2.51B | $12.59B | $10.53B | — | +162.5% |
| Total liabilities | $20.85B | $7.94B | $29.59B | $22.88B | — | +162.4% |
| Retained earnings | -$53.18B | -$52.49B | -$39.35B | -$13.18B | — | -1.3% |
| Shareholder equity | $50.80B | $36.85B | $22.91B | $48.87B | — | +37.8% |
| Working capital | $20.61B | $20.97B | -$10.91B | -$2.81B | — | -1.7% |
| Net tangible assets | $44.68B | $36.84B | $19.17B | $41.54B | — | +21.3% |
| Shares issued | 12.95M | 9.81M | 5.94M | 5.94M | — | +32.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $12.80M | -$13.27B | -$26.51B | -$18.13B | — | +100.1% |
| Depreciation & amortisation | $1.23B | $852.45M | $871.12M | $1.23B | — | +43.8% |
| Stock-based compensation | — | $47.30M | $189.74M | $208.70M | $51.26M | — |
| Change in working capital | -$9.01B | -$830.12M | $1.16B | $165.48M | — | -984.8% |
| Operating cash flow | -$2.16B | -$3.84B | -$3.77B | -$8.83B | — | +43.8% |
| Capital expenditure | -$467.71M | -$30.80M | -$27.50M | -$560.98M | — | -1,418.3% |
| Investing cash flow | -$21.03B | $6.93B | -$3.12B | -$10.72B | — | -403.5% |
| Share buybacks | — | — | — | — | -$183.33M | — |
| Financing cash flow | $6.88B | $18.74B | $7.19B | -$2.77B | — | -63.3% |
| Free cash flow | -$2.62B | -$3.87B | -$3.80B | -$9.39B | — | +32.2% |
| End cash position | $7.00B | $23.32B | $1.31B | $989.11M | — | -70.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $17.48B | $16.41B | $16.05B | $19.09B | $1.62B | +6.5% |
| Operating revenue | $17.48B | $16.41B | $16.05B | $19.09B | $1.62B | +6.5% |
| Cost of revenue | $15.48B | $12.70B | $11.48B | $14.93B | $754.91M | +22.0% |
| Gross profit | $1.99B | $3.71B | $4.57B | $4.16B | $864.15M | -46.3% |
| Research & development | $998.00K | $870.00K | $622.00K | $908.00K | $3.98M | +14.7% |
| Selling, general & admin | $677.17M | $570.49M | $517.31M | $536.32M | $434.32M | +18.7% |
| Total operating expense | $3.09B | $3.38B | $2.38B | $2.76B | $1.25B | -8.7% |
| Operating income | -$1.09B | $332.13M | $2.19B | $1.40B | -$387.17M | -428.6% |
| Net interest income | $56.96M | $116.26M | $124.21M | $131.62M | -$46.14M | -51.0% |
| Pre-tax income | -$1.73B | -$3.28B | $2.32B | $1.99B | -$178.00M | +47.3% |
| Tax provision | $18.24M | $388.11M | $219.66M | $225.70M | $9.31M | -95.3% |
| Net income | -$1.64B | -$3.85B | $1.80B | $1.43B | -$187.31M | +57.5% |
| Net income to common | -$1.64B | -$3.85B | $1.80B | $1.43B | -$187.31M | +57.5% |
| Basic EPS | -130.00 | — | 185.00 | 145.00 | -20.00 | — |
| Diluted EPS | -130.00 | — | 180.00 | 145.00 | -20.00 | — |
| EBIT | -$1.61B | -$3.19B | $2.41B | $2.11B | -$52.69M | +49.5% |
| EBITDA | -$1.22B | -$2.81B | $2.79B | $2.48B | $24.76M | +56.4% |
| Basic shares | 12.56M | — | 9.82M | 9.82M | 9.82M | — |
| Diluted shares | 12.56M | — | 10.01M | 9.82M | 9.82M | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $7.26B | $7.00B | $16.04B | $13.84B | $23.99B | +3.7% |
| Cash & short-term investments | $12.74B | $21.12B | $38.65B | $37.04B | $24.10B | -39.7% |
| Accounts receivable | $7.33B | $6.88B | $8.01B | $7.88B | $1.54B | +6.5% |
| Inventory | $29.75M | — | — | — | — | — |
| Total current assets | $36.57B | $38.89B | $57.87B | $52.15B | $33.44B | -6.0% |
| Property, plant & equipment | $6.83B | $2.83B | $2.95B | $3.06B | $775.10M | +141.3% |
| Goodwill & intangibles | $8.74B | $6.11B | $5.65B | $5.88B | $64.92M | +43.0% |
| Total assets | $78.76B | $74.86B | $79.29B | $75.09B | $52.57B | +5.2% |
| Total current liabilities | $24.16B | $18.28B | $18.45B | $22.30B | $6.92B | +32.2% |
| Current debt | $9.80B | $4.60B | $4.59B | $4.70B | $480.91M | +112.8% |
| Long-term debt | $1.14B | $1.25B | $1.36B | $1.47B | — | -8.6% |
| Total debt | $11.35B | $6.59B | $6.80B | $7.07B | $1.24B | +72.1% |
| Total liabilities | $26.48B | $20.85B | $21.66B | $25.81B | $7.99B | +27.0% |
| Retained earnings | -$54.81B | -$53.18B | -$49.46B | -$51.25B | -$52.68B | -3.1% |
| Shareholder equity | $49.17B | $50.80B | $54.61B | $45.76B | $44.58B | -3.2% |
| Working capital | $12.40B | $20.61B | $39.43B | $29.85B | $26.52B | -39.8% |
| Net tangible assets | $40.43B | $44.68B | $48.96B | $39.88B | $44.52B | -9.5% |
| Shares issued | 13.11M | 12.95M | 12.16M | 9.97M | 9.97M | +1.2% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$1.75B | -$3.67B | $2.10B | $1.77B | -$187.31M | — | +52.4% |
| Depreciation & amortisation | $389.07M | $384.79M | $384.85M | $378.38M | $77.45M | — | +1.1% |
| Stock-based compensation | — | — | — | — | — | $0 | — |
| Change in working capital | -$3.53B | $2.69B | -$7.49B | -$4.17B | -$38.36M | — | -231.2% |
| Operating cash flow | -$4.34B | $5.63B | -$4.81B | -$2.60B | -$363.70M | — | -177.2% |
| Capital expenditure | -$29.24M | -$21.56M | -$1.18M | -$365.44M | -$79.52M | — | -35.6% |
| Investing cash flow | $4.53B | -$14.41B | $1.44B | -$3.66B | -$4.40B | — | +131.5% |
| Financing cash flow | -$28.02M | -$254.04M | $5.51B | -$3.82B | $5.44B | — | +89.0% |
| Free cash flow | -$4.37B | $5.61B | -$4.82B | -$2.97B | -$443.23M | — | -178.0% |
| End cash position | $7.26B | $7.00B | $16.04B | $13.84B | $23.99B | — | +3.7% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Mar 2016 | 1,045.00 | 90.00 | -91.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1,777.20
-6.31% from price
SMA 20
1,719.30
-3.16% from price
SMA 50
1,587.94
+4.85% from price
SMA 100
1,790.34
-7.00% from price
SMA 200
2,250.00
-26.00% from price
EMA 12
1,734.18
-3.99% from price
EMA 26
1,706.09
-2.41% from price
EMA 50
1,701.60
-2.15% from price
RSI (14)
46.6
Neutral
MACD (12,26,9)
28.09
Hist -14.19
ATR (14)
95.71
5.75% of price
Realised vol 30D
50.0%
Annualised
Bollinger upper
1,881.27
20, 2σ
Bollinger lower
1,557.33
20, 2σ
50 / 200 cross
Death
1,587.94 vs 2,250.00
Trend bias
Below 200
-26.00%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.04
Less volatile than market
Correlation to SPY
-0.01
Largely independent
Realised vol 30D
50.0%
Annualised
Market vol 1Y
12.8%
SPY, annualised
Max drawdown 1Y
-64.8%
Peak to trough
Max drawdown 5Y
-93.9%
Peak to trough
ATR 14
95.71
5.75% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
FDA places clinical hold on REGENXBIO’s RGX-121 in MPS II trial
Clinical Trials Arena · 2m ago
Morning Bid: Economic salvos
Reuters · 3m ago
Takeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1
Hospital Management · 7m ago
SealingTech, a Parsons Corporation company, receives $750 Million Joint Cyber Hunt Kit (JCHK) Full-Rate Production Award from USCYBERCOM
PR Newswire · 9m ago
One in Three U.S. Women Are Already Using AI for Skincare and Bodycare Advice, New Survey Finds
PR Newswire · 9m ago
Innovent Announces 2026 Interim Results and Business Updates
PR Newswire · 9m ago
RBC creates unified Global Transaction Banking business, combining strengths across leading businesses
PR Newswire · 9m ago
Student Storytellers at Boys & Girls Clubs of Twin Cities Take Center Stage at Dream to Screen Awards Powered by Epson, with Special Appearance by Epson Ambassador Shaquille O'Neal
PR Newswire · 9m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.